Podoplanin belongs to a type-I transmembrane protein which is a sialoglycoprotein with some O-glycosylation sites. It is known as a lymphatic endothelium-specific marker and believed to have a platelet-aggregating activity and to promote hematogenous metastasis of cancer cells. Podoplanin is thought to be expressed on the shape alteration of squamous cells and to relate to transition of cytoskeletal actin structure. Also, its activity which decreases the adhesion ability of cells and promotes their metastasis has drawn researchers’ attention. Additionally, podoplanin is reported to be expressed in human tumors such as brain tumor, oral cavity cancer, head and neck cancer, esophageal cancer, lung cancer, testicular tumor, cervical cancer and malignant mesothelioma. For research use only, not for use in diagnostic procedures.